CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

All Clinical Trials for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00062764 ↗	Treating Nonalcoholic Steatohepatitis With Pioglitazone	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-06-01	Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol. The etiology of NASH is unclear, but it is commonly associated with diabetes, obesity, and insulin resistance. Several pilot studies, including a study of pioglitazone at the NIH Clinical Center (01-DK-0130), have shown that the insulin-sensitizing thiazolidinediones lead to decreases in serum alanine aminotransferase (ALT) levels and improved liver histology. Once therapy is stopped, however, ALT levels rapidly return to pre-treatment values. Inaddition we are currently enrolling patients with NASH in a pilot study of metformin therapy for 48-weeks, however our results in 3 patients thus far have not been very encouraging. In the current study, patients who have completed the pilot study of pioglitazone and have been off therapy for 48 weeks will be offered re-treatment for 3 years. We also propose to treat patients who have not had a satisfactory response to metformin with pioglitazone for the same duration. After a repeat medical and metabolic evaluation and liver biopsy, patients with moderate-to-severe NASH (activity score greater than or equal to 4) will restart pioglitazone at a dose of 15 mg daily. If after 48 weeks, ALT levels are not normal or improved to the degree identified during the pilot study, the dose will be increased to 30 mg daily at the end of 3 years, all patients will undergo repeat medical and metabolic evaluation and liver biopsy. The primary end point will be improvement in liver histology. Secondary end points will be improvements in insulin sensitivity, reduction in visceral fat, liver volume, and liver biochemistry. The aim of this study is to evaluate whether long-term pioglitazone therapy can safely achieve and maintain biochemical and histological improvements in NASH. ...
NCT00063232 ↗	Treating Nonalcoholic Steatohepatitis (NASH) With Metformin	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-06-01	Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance. At present, there are no approved treatments for NASH patients, but an experimental approach has focused on improving their insulin sensitivity. Metformin is one of the most commonly used medications for the treatment of diabetes. The purpose of this study is to determine whether the medical problems of NASH patients, specifically liver damage, improves when their insulin sensitivity is enhanced with metformin. The study will last 3 to 5 years and will enroll up to 30 patients. Participants will undergo a complete medical examination, a series of lab tests, and a liver biopsy. They will then start taking a single 500-mg tablet of metformin once a day for 2 weeks, then the same dosage twice a day for 2 more weeks, if they tolerate the first dosage. The dosage will increase to 1,000 mg twice a day for the remaining 44 weeks of the study. After 1 year, participants will undergo a repeat medical examination and liver biopsy.
NCT00097279 ↗	Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes	Completed	Novo Nordisk A/S	Phase 3	2004-08-01	This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood glucose.
NCT00108615 ↗	Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance	Completed	US Department of Veterans Affairs	Phase 4	2004-01-01	Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.
NCT00108615 ↗	Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance	Completed	VA Office of Research and Development	Phase 4	2004-01-01	Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.
NCT00159211 ↗	Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin	Terminated	Laboratoires Takeda	N/A	2005-05-01	In type 2 diabetic patients with poor glycemic control despite maximum "classic" oral treatment, bed time insulin therapy may lead to a parallel increase in abdominal visceral and subcutaneous fat, whereas pioglitazone treatment should lead to a stability (or even a decrease ) in visceral and an increase in subcutaneous abdominal fat. As visceral fat mass is correlated with insulin-resistance and cardio-vascular risk, the evolution of visceral abdominal fat in type 2 diabetic patients is of great importance. Main objective: To compare visceral and subcutaneous abdominal fat compartment after a six-month bed time insulin or pioglitazone treatment in type 2 diabetic patients with poor glycemic control despite a maximal oral treatment with metformin and sulfonylureas. The study hypothesis is that quantity of visceral and subcutaneous abdominal adipose tissue should differently evolute comparing a 6 month treatment with pioglitazone® (30 or 45mg/j) or NPH " bed-time " insulin (0.2u/kg/

Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Condition Name

Condition Name for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Intervention	Trials
Diabetes Mellitus, Type 2	31
Type 2 Diabetes Mellitus	30
Type 2 Diabetes	25
Diabetes Mellitus	20

Condition MeSH

Condition MeSH for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Intervention	Trials
Diabetes Mellitus	108
Diabetes Mellitus, Type 2	102
Fatty Liver	15
Non-alcoholic Fatty Liver Disease	13

Clinical Trial Locations for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Trials by Country

Trials by Country for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Location	Trials
United States	788
Germany	44
Canada	40
India	40
Mexico	30

Trials by US State

Trials by US State for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Location	Trials
Texas	38
Florida	30
California	30
North Carolina	27
Georgia	25

Clinical Trial Progress for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	4
PHASE1	3

Clinical Trial Status

Clinical Trial Status for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	106
RECRUITING	18
Unknown status	17

Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

Sponsor Name

Sponsor Name for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Sponsor	Trials
Takeda	21
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	8
Novo Nordisk A/S	8

Sponsor Type

Sponsor Type for METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
Sponsor	Trials
Other	144
Industry	91
NIH	9

Last updated: July 30, 2026

Metformin Hydrochloride and Pioglitazone Hydrochloride Clinical Trials Update, Market Analysis, and Forecast

Metformin hydrochloride and pioglitazone hydrochloride are mature oral diabetes therapies with established global market penetration. Near-term clinical trial activity concentrates on (1) fixed-dose and combination formulations, (2) mechanistic and biomarker studies, (3) cardiometabolic and renal outcomes, and (4) safety and adherence strategies. Commercially, demand is driven by persistent type 2 diabetes prevalence, guideline-based first-line use for metformin, and pioglitazone’s role in combination regimens where insulin-sparing effects and cardiovascular benefit signals matter. Pricing pressure, generic competition, and safety monitoring constraints (notably pioglitazone edema/weight gain and bladder cancer risk language) shape growth rates and competitive dynamics.

---

What clinical trials are updating for metformin and pioglitazone in 2024 to 2026?

Core themes across recent trial programs

1. Combination positioning and fixed-dose products

   • Metformin remains the backbone of oral diabetes regimens.
   • Pioglitazone is tested as an add-on in combination strategies to improve glycemic control while reducing insulin escalation.
   • Trials increasingly evaluate adherence, time-in-therapy, and “real-world effectiveness” endpoints alongside A1c.

2. Cardiovascular, renal, and outcomes endpoints

   • Metformin programs continue to evaluate kidney-related effects and cardiovascular risk modulation in broader populations, including patients with chronic kidney disease.
   • Pioglitazone trials focus on cardiovascular outcomes and metabolic inflammation pathways, using risk stratification and imaging/biomarker endpoints.

3. Safety, tolerability, and discontinuation

   • Pioglitazone programs track edema incidence, weight trajectories, and heart failure (HF) risk screening and management strategies.
   • Metformin programs evaluate gastrointestinal tolerability, renal thresholds, and dose optimization protocols.

4. Mechanism-of-action and patient subgroup analytics

   • Metformin trials often include pharmacodynamic readouts and mitochondrial/metabolic biomarkers.
   • Pioglitazone trials increasingly examine insulin sensitization and adipose tissue signaling using metabolomic panels.

Which trial phases are most active for these drugs?

Answer: The majority of non-postmarketing updates are Phase 3/4 (comparative efficacy, cardiovascular/renal endpoints, adherence/switch studies) and Phase 2 for mechanistic biomarker designs. Because both actives are off-patent in major markets, the “pipeline” is dominated by combination, formulation, and outcomes studies rather than new molecular entities.

What study endpoints are being emphasized?

• A1c change and proportion achieving target thresholds (often 6 to 12 months)
• Composite cardiovascular outcomes in pioglitazone-adjacent studies
• Estimated glomerular filtration rate (eGFR) trajectories and renal safety in metformin studies
• Weight change and edema incidence for pioglitazone
• Discontinuation rates, dose persistence, and adherence metrics for both

---

How does metformin clinical evidence compare with pioglitazone for type 2 diabetes outcomes?

Quick comparison

• Metformin: strongest evidence base for first-line therapy; consistent glycemic reduction; renal safety management is central in modern practice.
• Pioglitazone: strong insulin-sensitizer; outcome studies support cardiovascular risk reduction signals in certain populations; trade-offs include weight gain, edema, and ongoing benefit-risk framing versus bladder cancer labeling history.

Where do the drugs differ most in trial behavior?

• Metformin trials often expand to CKD and “risk management” protocols.
• Pioglitazone trials are more frequently anchored to cardiovascular and metabolic syndrome phenotypes and weigh safety management strategies as co-primary considerations.

---

Which fixed-dose combinations and combination regimens are driving new metformin and pioglitazone studies?

Combination patterns showing repeat study designs

• Metformin + pioglitazone as a dual oral regimen target for patients inadequately controlled on monotherapy.
• Metformin + other oral agents (DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonist add-on via titration comparisons in pragmatic studies).
• Pioglitazone add-on strategies where insulin-sparing and weight effects are managed through diet, titration, and monitoring protocols.

What is the typical trial design for these combinations?

• randomized, open-label comparative trials
• add-on or switch designs in real-world settings
• pharmacokinetic or bioequivalence studies for fixed-dose formulations
• adherence and persistence endpoints for pragmatic comparison

---

What is the market size for metformin and pioglitazone globally, and what are the growth drivers?

Market structure

• Both are long-established oral diabetes drugs with extensive generic penetration.
• Growth is driven by patient pool expansion and treatment line persistence, offset by pricing pressure from generics and payer contracting.

Key growth drivers

• Rising type 2 diabetes prevalence and expanding diagnosed rates
• Guideline inclusion for metformin as default first-line
• Pioglitazone’s role as an affordable oral add-on where GLP-1 RA and SGLT2 inhibitors are constrained by cost or access
• Continued inclusion in health-system formularies for cost-effectiveness

Key headwinds

• Continued erosion of branded pricing in many geographies
• Safety-driven restrictions and clinician caution (especially pioglitazone)
• Patent-free environment reduces incentives for large new R&D spend by originators

---

When does metformin and pioglitazone lose exclusivity and what does that mean for competition?

Answer: In major markets, both actives are already beyond primary patent exclusivity, with competition dominated by generics and authorized generics. The remaining “exclusivity” value tends to be tied to:

• formulation-specific patents (fixed-dose combinations, polymorphs, manufacturing methods)
• branded product lifecycle protections in specific countries
• data exclusivity only where applicable to specific reformulations or new combination products

What competition scenarios matter most commercially?

• Generic substitution in formularies
• Tender-driven pricing in EU public procurement and other systems
• Authorized generics and multi-source supply affecting market share stability

---

What does the Orange Book status imply for metformin and pioglitazone generics?

Answer: Orange Book listings typically show extensive generic availability for both actives, with many products far beyond any exclusivity windows. Market access risk is therefore less about “Paragraph IV” patent cliffs for the active ingredient and more about:

• formulation-level patents (fixed-dose or new salts)
• any remaining labeling or method-of-use protection for specific indications or patient populations
• brand-to-generic substitution behavior by payers and PBMs

(Specific Orange Book listing counts and expiration dates require product-by-product entry inspection; this analysis avoids unverified listing enumeration.)

---

What patent and IP barriers could affect combination launches (metformin + pioglitazone)?

Most common IP friction points

• patents on fixed-dose combinations (dose ratios and titration regimens)
• formulation patents (extended-release or bioavailability improvements)
• manufacturing process patents for specific polymorphs or particle sizes
• method-of-use patents tied to specific outcome-optimizing protocols, if any remain in targeted jurisdictions

How does this translate to generic launch risk?

• If no active formulation or method-of-use barriers remain, launch risk is mainly supply and regulatory rather than litigation.
• If formulation-specific patents still exist in a jurisdiction, the primary barrier is often injunction risk around bioequivalence and formulation equivalence claims.

---

How strong is the safety and labeling risk profile affecting pioglitazone adoption?

Safety themes that show up in real-world switching and persistence

• Edema and weight gain: affects adherence and clinician willingness to titrate.
• Heart failure monitoring: affects patient selection and discontinuation.
• Bladder cancer risk language: shapes risk-benefit framing, particularly in patients with urinary tract disease history.

What trial outcomes tend to change prescribing behavior?

• reductions in glycemic endpoints without unacceptable discontinuations
• edema incidence management strategies
• subgroup outcomes for cardiovascular risk categories
• discontinuation reasons and persistence by patient baseline risk

---

What is the competitive landscape for metformin and pioglitazone by geography?

United States

• Multi-source generic environment dominates.
• Competitive differentiation is driven by:
  • formulation tolerability and tablet size
  • dosing convenience (including combination products)
  • pharmacy contracting and wholesaler supply stability

Europe

• Similar generic-driven markets.
• Tender pricing strongly influences share.

Emerging markets

• Growth still occurs where diagnosed prevalence and treatment coverage expand.
• Supply reliability and local regulatory approvals can dominate competitive outcomes.

---

What revenue exposure do metformin and pioglitazone face under generic pricing pressure?

Answer: Revenue upside is constrained by low-cost generic benchmarks; profit pool shifts toward:

• combination products with differentiated formulations
• payer-specific contracts and multi-year tenders
• supply chain advantages and consistent manufacturing quality

Where is the profit pool most likely to sit?

• fixed-dose combinations with convenience value
• markets with slower switching due to clinician preference or limited formulary updates
• channels where patient education and titration programs reduce drop-off

---

What are the most likely near-term market forecasts for metformin and pioglitazone through 2028?

Forecast direction

• Metformin: modest-to-steady unit growth aligned with diabetes prevalence; price per unit likely flat-to-down in generic markets.
• Pioglitazone: more volatile by country due to safety framing, prescriber behavior, and payer restrictions; moderate growth potential where clinicians prioritize oral insulin-sensitizing add-on strategies and cost constraints favor older agents.

Scenario framework (directional, not point estimates)

• Base case: gradual unit growth, price compression continues, combination products gain share.
• Downside: stronger payer pushes toward SGLT2/GLP-1 preferred pathways reduce pioglitazone utilization; increased safety-driven discontinuations.
• Upside: cost and access limitations for newer therapies expand pioglitazone use in combination regimens; improved fixed-dose tolerability increases persistence.

---

Key Takeaways

• Clinical update activity for metformin and pioglitazone is dominated by combination regimens, fixed-dose strategies, and outcomes/safety studies rather than novel MOAs.
• The markets remain generic-led; commercial gains depend on tender pricing, combination differentiation, and persistence, not exclusivity.
• Pioglitazone growth is structurally tied to safety management and payer/clinician willingness to use an oral insulin-sensitizer in appropriate phenotypes.
• Near-term forecasts through 2028 are steady volume growth with continued price pressure, with combination products capturing incremental share.

---

FAQs

1. Are metformin and pioglitazone used together in current clinical practice, and how do outcomes compare to other combinations?
2. Do fixed-dose metformin–pioglitazone products have formulation-specific patent or regulatory advantages over single-entity generics?
3. What safety monitoring protocols reduce pioglitazone discontinuation in routine care?
4. How do kidney function thresholds influence metformin persistence and dose optimization in trials?
5. What payer policies most affect pioglitazone utilization versus SGLT2 inhibitors and GLP-1 receptor agonists?

---

References

1. APA. (n.d.). Publication manual. American Psychological Association.
2. FDA. (n.d.). Drug approvals and labeling information for diabetes therapies. U.S. Food and Drug Administration.
3. ClinicalTrials.gov. (n.d.). Metformin and pioglitazone trial records. U.S. National Library of Medicine.